Tomoyuki Mizuno

Peer Reviewed Publications

Hahn D.;Fukuda T.;Euteneuer J.C.;Mizuno T.;Vinks A.A.;Sadhasivam S.;Emoto C.  (08-01-2020). Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and . Journal of Clinical Pharmacology, 60 (8) , 992-998More Information

van Hoogdalem M.W.;Emoto C.;Fukuda T.;Mizuno T.;Mehta P.A.;Vinks A.A.  (05-01-2020). Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric. British Journal of Clinical Pharmacology, 86 (5) , 933-943More Information

Bauman L.E.;Xiong Y.;Mizuno T.;Minar P.;Fukuda T.;Dong M.;Rosen M.J.;Vinks A.A.  (02-11-2020). Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric . Inflammatory Bowel Diseases, 26 (3) , 429-439More Information

Emoto C.;Hahn D.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T.  (02-01-2020). Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted. Clinical Pharmacology and Therapeutics, 107 (2) , 319-320More Information

Mizuno T.;Dong M.;Taylor Z.L.;Ramsey L.B.;Vinks A.A.  (01-01-2020). Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient c. British Journal of Clinical PharmacologyMore Information

Tang Girdwood S.C.;Mizuno T.;Krallman K.A.;Benken L.A.;Stoneman E.M.;Yunger T.M.;Wong H.R.;Vinks A.A.;Kaplan J.M.  (01-01-2020). Route of oseltamivir administration affects metabolite concentrations in critically ill children. Pediatric Infectious Disease Journal, 1224-1227More Information

Taylor Z.L.;Mizuno T.;Punt N.C.;Baskaran B.;Navarro Sainz A.;Shuman W.;Felicelli N.;Vinks A.A.;Heldrup J.;Ramsey L.B.  (01-01-2020). MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to In. Clinical Pharmacology and TherapeuticsMore Information

Vinks A.A.;Punt N.C.;Menke F.;Kirkendall E.;Butler D.;Duggan T.J.;Cortezzo D.M.E.;Kiger S.;Dietrich T.;Spencer P.;Keefer R.;Setchell K.D.R.;Zhao J.;Euteneuer J.C.;Mizuno T.;Dufendach K.R.  (01-01-2020). Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonate. Clinical Pharmacology and Therapeutics, 107 (1) , 186-194More Information

McGann P.T.;Niss O.;Dong M.;Marahatta A.;Howard T.A.;Mizuno T.;Lane A.;Kalfa T.A.;Malik P.;Quinn C.T.;Ware R.E.;Vinks A.A.  (08-01-2019). Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for y. American Journal of Hematology, 94 (8) , 871-879More Information

Mizuno T.;Gist K.M.;Gao Z.;Wempe M.F.;Alten J.;Cooper D.S.;Goldstein S.L.;Vinks A.A.  (06-01-2019). Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infant. Clinical Pharmacokinetics, 58 (6) , 793-803More Information

Brunet M.;Van Gelder T.;Åsberg A.;Haufroid V.;Hesselink D.;Langman L.;Lemaitre F.;Marquet P.;Seger C.;Shipkova M.;Vinks A.;Wallemacq P.;Wieland E.;Woillard J.;Barten M.;Budde K.;Colom H.;Dieterlen M.;Elens L.;Johnson-Davis K.;Kunicki P.;Macphee I.;Masuda S.;Mathew B.;Millán O.;Mizuno T.;Moes D.;Monchaud C.;Noceti O.;Pawinski T.;Picard N.;Van Schaik R.;Sommerer C.;Vethe N.;De Winter B.;Christians U.;Bergan S.  (06-01-2019). Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 41 (3) , 261-307More Information

Ramsey L.;Mizuno T.;Vinks A.;O'Brien M.  (05-01-2019). Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving . Pediatric Blood and Cancer, 66 (5) More Information

Hahn D.;Emoto C.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T.  (03-01-2019). Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates:. Clinical Pharmacology and Therapeutics, 105 (3) , 761-768More Information

Mizuno T.;O'Brien M.;Vinks A.  (02-01-2019). Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediat. European Journal of Pharmaceutical Sciences, 128, 209-214More Information

Boucher A.;Mizuno T.;Vinks A.;Goldstein S.;Tiao G.;Geller J.  (01-01-2019). Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for . Pediatric Blood and Cancer, 66 (1) More Information

Kaplan J.M.;Zingarelli B.;Krallman K.;Tang Girdwood S.;Lagory D.;Mizuno T.;Fei L.;Wong H.R.;Vinks A.A.  (11-01-2018). Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with . Intensive Care Medicine, 44 (11) , 2006-2008More Information

Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A.  (07-01-2018). Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide . British Journal of Clinical Pharmacology, 84 (7) , 1410-1412More Information

Gist K.;Cooper D.;Wrona J.;Faubel S.;Altmann C.;Gao Z.;Marino B.;Alten J.;Hock K.;Mizuno T.;Vinks A.;Joy M.;Wempe M.;Bennett M.;Goldstein S.  (04-01-2018). Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Ser. Therapeutic Drug Monitoring, 40 (2) , 186-194More Information

Mizuno T.;Emoto C.;Fukuda T.;Hammill A.;Adams D.;Vinks A.  (11-15-2017). Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies. European Journal of Pharmaceutical Sciences, 109, S124-S131More Information

Alloway R.R.;Vinks A.A.;Fukuda T.;Mizuno T.;King E.C.;Zou Y.;Jiang W.;Woodle E.S.;Tremblay S.;Klawitter J.;Klawitter J.;Christians U.  (11-01-2017). Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A. PLoS Medicine, 14 (11) More Information

Dong M.;Mizuno T.;Vinks A.  (09-01-2017). Opportunities for model-based precision dosing in the treatment of sickle cell anemia. Blood Cells, Molecules, and Diseases, 67, 143-147More Information

Mizuno T.;Fukuda T.;Emoto C.;Mobberley-Schuman P.;Hammill A.;Adams D.;Vinks A.  (08-01-2017). Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infan. Pediatric Blood and Cancer, 64 (8) More Information

Faircloth J.M.;Miner K.M.;Alsaied T.;Nelson N.;Ciambarella J.;Mizuno T.;Palumbo J.S.;Vinks A.A.;Veldtman G.R.  (07-01-2017). Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients. Journal of Thrombosis and Thrombolysis, 44 (1) , 38-47More Information

Diwan T.;Lichvar A.;Leino A.;Vinks A.;Christians U.;Shields A.;Cardi M.;Fukuda T.;Mizuno T.;Kaiser T.;Woodle E.;Alloway R.  (06-01-2017). Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve g. Clinical Transplantation, 31 (6) More Information

Balyan R.;Zhang X.;Chidambaran V.;Martin L.;Mizuno T.;Fukuda T.;Vinks A.;Sadhasivam S.  (05-01-2017). OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children. Pharmacogenomics, 18 (7) , 621-629More Information

Ramsey L.;Mizuno T.;Vinks A.;Margolis P.  (03-01-2017). Learning Health Systems as Facilitators of Precision Medicine. Clinical Pharmacology and Therapeutics, 101 (3) , 359-367More Information

Chidambaran V.;Venkatasubramanian R.;Zhang X.;Martin L.;Niu J.;Mizuno T.;Fukuda T.;Meller J.;Vinks A.;Sadhasivam S.  (03-01-2017). ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and. Pharmacogenomics Journal, 17 (2) , 162-169More Information

Mizuno T.;Fukuda T.;Christians U.;Perentesis J.;Fouladi M.;Vinks A.  (01-01-2017). Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: . British Journal of Clinical Pharmacology, 83 (5) , 1097-1107More Information

Cabrera-Salcedo C.;Mizuno T.;Tyzinski L.;Andrew M.;Vinks A.A.;Frystyk J.;Wasserman H.;Gordon C.M.;Hwa V.;Backeljauw P.;Dauber A.  (01-01-2017). Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and. Journal of Clinical Endocrinology and Metabolism, 102 (12) , 4568-4577More Information

Chidambaran V.;Pilipenko V.;Spruance K.;Venkatasubramanian R.;Niu J.;Fukuda T.;Mizuno T.;Zhang K.;Kaufman K.;Vinks A.;Martin L.;Sadhasivam S.  (01-01-2017). Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and p. Pharmacogenomics, 18 (2) , 143-156More Information

Emoto C.;Fukuda T.;Mizuno T.;Schniedewind B.;Christians U.;Adams D.;Vinks A.  (08-01-2016). Characterizing the developmental trajectory of sirolimus clearance in neonates and infants. CPT: Pharmacometrics and Systems Pharmacology, 5 (8) , 411-417More Information

Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A.  (04-01-2016). Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in. British Journal of Clinical Pharmacology, 81 (4) , 742-752More Information

Hahn A.;Fukuda T.;Hahn D.;Mizuno T.;Frenck R.;Vinks A.  (04-01-2016). Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia. Pharmacogenomics, 17 (6) , 547-559More Information

Nehus E.;Mizuno T.;Cox S.;Goldstein S.;Vinks A.  (03-01-2016). Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation. Journal of clinical pharmacology, 56 (3) , 291-297More Information

Wiles J.;Isemann B.;Mizuno T.;Tabangin M.;Ward L.;Akinbi H.;Vinks A.  (12-01-2015). Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study. The Journal of pediatrics, 167 (6) , 1214-1220.e3More Information

Gist K.M.;Mizuno T.;Goldstein S.L.;Vinks A.  (01-01-2015). Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury. Therapeutic Drug Monitoring, 37 (6) , 792-796More Information

Emoto C.;Fukuda T.;Mizuno T.;Cox S.;Schniedewind B.;Christians U.;Widemann B.C.;Fisher M.J.;Weiss B.;Perentesis J.;Vinks A.A.  (01-01-2015). Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1. Therapeutic Drug Monitoring, 37 (3) , 395-399More Information

Fukudo M.;Ito T.;Mizuno T.;Shinsako K.;Hatano E.;Uemoto S.;Kamba T.;Yamasaki T.;Ogawa O.;Seno H.;Chiba T.;Matsubara K.  (02-01-2014). Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepat. Clinical Pharmacokinetics, 53 (2) , 185-196More Information

Venkatasubramanian R.;Fukuda T.;Niu J.;Mizuno T.;Chidambaran V.;Vinks A.;Sadhasivam S.  (01-01-2014). ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children. Pharmacogenomics, 15 (10) , 1297-1309More Information

Mizuno T.;Fukuda T.;Masuda S.;Uemoto S.;Matsubara K.;Inui K.;Vinks A.  (01-01-2014). Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children. British Journal of Clinical Pharmacology, 77 (5) , 910-912More Information

Ishii T.;Hatano E.;Taura K.;Mizuno T.;Kawai T.;Fukudo M.;Katsura T.;Uemoto S.  (01-01-2014). Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic stud. Hepatology Research, 44 (6) , 685-688More Information

Mizuno T.;Fukudo M.;Fukuda T.;Terada T.;Dong M.;Kamba T.;Yamasaki T.;Ogawa O.;Katsura T.;Inui K.I.;Vinks A.A.;Matsubara K.  (01-01-2014). The Effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal . Therapeutic Drug Monitoring, 36 (3) , 310-316More Information

Kunimatsu S.;Mizuno T.;Fukudo M.;Katsura T.  (08-01-2013). Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of . Drug Metabolism and Disposition, 41 (8) , 1592-1597More Information

Fukuda T.;Chidambaran V.;Mizuno T.;Venkatasubramanian R.;Ngamprasertwong P.;Olbrecht V.;Esslinger H.;Vinks A.;Sadhasivam S.  (01-01-2013). OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics, 14 (10) , 1141-1151More Information

Togashi Y.;Masago K.;Masuda S.;Mizuno T.;Fukudo M.;Ikemi Y.;Sakamori Y.;Nagai H.;Kim Y.;Katsura T.;Mishima M.  (09-01-2012). Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung ca. Cancer Chemotherapy and Pharmacology, 70 (3) , 399-405More Information

Mizuno T.;Fukudo M.;Terada T.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.;Katsura T.  (01-01-2012). Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacoki. Drug Metabolism and Pharmacokinetics, 27 (6) , 631-639More Information

Shinsako K.;Mizuno T.;Terada T.;Watanabe J.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.  (10-01-2010). Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study. International Journal of Clinical Oncology, 15 (5) , 512-514More Information

Mizuno T.;Terada T.;Kamba T.;Fukudo M.;Katsura T.;Nakamura E.;Ogawa O.;Inui K.  (02-06-2010). ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcino. Annals of Oncology, 21 (6) , 1382-1383More Information

Tsuda M.;Terada T.;Mizuno T.;Katsura T.;Shimakura J.;Inui K.  (06-01-2009). Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secret. Molecular Pharmacology, 75 (6) , 1280-1286More Information

Mizuno T.;Mohri K.;Nasu S.;Danjo K.;Okamoto H.  (03-04-2009). Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bi. Journal of Controlled Release, 134 (2) , 149-154More Information

Kodawara T.;Mizuno T.;Taue H.;Hashida T.;Yano I.;Katsura T.;Inui K.  (03-01-2009). Evaluation of stability of temozolomide in solutions after opening the capsule. Yakugaku Zasshi, 129 (3) , 353-357More Information